Company intelligence / Profile preview

ProPhet

Rehovot (AION Labs hub), Central District, Israel

Ownership: Private
Development stage: Other

Overview

ProPhet is a recently launched AI-enabled drug discovery company that accelerates the identification of small molecule drug candidates targeting difficult protein structures, enabling screening of chemical libraries in days instead of years. No clinical development results are yet disclosed, as the company focuses on early-stage discovery.

Therapeutic areas: Other
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

AION Labs consortium partners: AstraZenecaMerckPfizerTeva PharmaceuticalsIsrael Biotech FundAmazon Web ServicesBioMed X

Beyond the preview

Go deeper on ProPhet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProPhet.

Explore the full profile